Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Comparative oncology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    59 result(s) found for: Comparative oncology. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-000398-64 Sponsor Protocol Number: VHIO18001 Start Date*: 2018-06-18
    Sponsor Name:Vall d' Hebron Institute of Oncology (VHIO)
    Full Title: Patterns of uptake of 18F-FDG and 68Ga-DOTA PET in advanced neuroendoctrine tumors
    Medical condition: Gastroenteropancreatic neuroendocrine tumor disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001811-16 Sponsor Protocol Number: PS21GAP Start Date*: 2022-12-19
    Sponsor Name:Princess Maxima Center for pediatric oncology
    Full Title: 68Ga-SATO in pediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001437-40 Sponsor Protocol Number: KO-TIP-007 Start Date*: 2019-03-08
    Sponsor Name:Kura Oncology, Inc.
    Full Title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM...
    Medical condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063569 Metastatic squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) NO (Completed) BE (Completed) AT (Completed) NL (Completed) GR (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003231-19 Sponsor Protocol Number: GO29294 Start Date*: 2015-01-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR M...
    Medical condition: Advanced tumor and metastastic disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) PL (Completed) SI (Completed) SE (Completed) DE (Completed) GB (Completed) HU (Completed) PT (Completed) NL (Completed) FI (Completed) NO (Completed) DK (Completed) BE (Completed) AT (Completed) ES (Completed) FR (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-003889-39 Sponsor Protocol Number: NALPAC Start Date*: 2021-10-11
    Sponsor Name:Belgian Group of Digestive Oncology (BGDO)
    Full Title: A Non-Comparative Randomized Phase 2 Study, Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Progressive After Gemcitabine-Abra...
    Medical condition: Pancreatic ductal adenocarcinoma (PDAC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004841-17 Sponsor Protocol Number: NEO-TIM Start Date*: 2020-08-18
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A phase II randomized non-comparative study, with neoadjuvant plus adjuvant therapy with combination or sequence of vemurafenib, cobImetinib, and atezolizuMab in patients with high-risk, surgically...
    Medical condition: high-risk, surgically resectable BRAF mutated and wild-type melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003185-27 Sponsor Protocol Number: C17-02 Start Date*: 2018-04-18
    Sponsor Name:GERCOR
    Full Title: A non-comparative randomized 2:1 phase II study of docetaxel, cisplatin, and 5-fluorouracil in combination or not with atezolizumab in patients with metastatic or unresectable locally advanced squa...
    Medical condition: Metastatic or unresectable locally advanced squamous anal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002141 Anal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005993-24 Sponsor Protocol Number: MIP7 Start Date*: 2022-09-14
    Sponsor Name:ITEL TELECOMUNICAZIONI S.R.L.
    Full Title: Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients with Biochemical Recurrence of Prostate Cancer after Previous Treatment w...
    Medical condition: Patients with confirmed biochemical recurrence of Prostatic Cancer (PCa) after treatment with curative intention.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002524-34 Sponsor Protocol Number: 011941 Start Date*: 2006-02-01
    Sponsor Name:BAYER Healthcare AG
    Full Title: An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma
    Medical condition: Advanced Renal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) ES (Completed) BE (Completed) DK (Completed) PT (Prematurely Ended) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2023-000156-38 Sponsor Protocol Number: 20230123SE Start Date*: 2023-05-04
    Sponsor Name:Semmelweis University, Department of Internal Medicine and Oncology
    Full Title: Value-based health economic comparative study of subcutaneous and intravenous trastuzumab-pertuzumab for HER-2 positive metastatic breast cancer based on patient reported outcomes.
    Medical condition: HER-2 positive advanced breast cancer, locally unresectable or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004854-97 Sponsor Protocol Number: A8851019 Start Date*: 2008-01-15
    Sponsor Name:Pfizer Ltd
    Full Title: OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE...
    Medical condition: CANDIDAEMIA/INVASIVE CANDIDIASIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) BE (Completed) PT (Completed) NL (Completed) IT (Completed) SK (Completed) PL (Completed) CZ (Completed) DK (Completed) HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002940-26 Sponsor Protocol Number: 212082PCR3011 Start Date*: 2013-05-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Me...
    Medical condition: Metastatic Hormone-Naive Prostate Cancer (mHNPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) PT (Completed) FI (Completed) ES (Completed) IT (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed) BG (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-005081-17 Sponsor Protocol Number: ARV-471-BC-201 Start Date*: 2023-01-20
    Sponsor Name:Arvinas Estrogen Receptor, Inc. (Arvinas)
    Full Title: An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2– Breast Cancer in the Neoadjuvant Setting
    Medical condition: Post-menopausal women with ER+ HER2– breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004553-72 Sponsor Protocol Number: J2N-OX-JZNM(LOXO-BTK-20019) Start Date*: 2021-07-14
    Sponsor Name:Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) HU (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005101-31 Sponsor Protocol Number: AV001 Start Date*: 2014-06-17
    Sponsor Name:Pfizer Inc
    Full Title: A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
    Medical condition: Chronic Myeloid Leukemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) SE (Completed) CZ (Completed) HU (Completed) SK (Completed) FI (Completed) NO (Completed) ES (Completed) DK (Completed) NL (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003062-32 Sponsor Protocol Number: B1271004 Start Date*: 2011-12-20
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED PHASE 2 NON-COMPARATIVE STUDY OF THE EFFICACY OF PF-04691502 AND PF-05212384 IN PATIENTS WITH RECURRENT ENDOMETRIAL CANCER
    Medical condition: RECURRENT ENDOMETRIAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Prematurely Ended) ES (Completed) PL (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014463-39 Sponsor Protocol Number: 1.1 Start Date*: 2009-12-01
    Sponsor Name:Celltrion, Inc.
    Full Title: A Double-blind Randomised, Parallel Phase I/IIb Study to Evaluate Initial Safety and Efficacy, Comparative Pharmacokinetics and Immunogenicity for CT-P6 and Herceptin in Metastatic Breast Cancer
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed) BG (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-001460-32 Sponsor Protocol Number: EOP1013B Start Date*: 2006-02-15
    Sponsor Name:Pfizer Inc
    Full Title: A phase 2/3 randomized, controlled, double-masked, multicenter, comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of 0.3 mg pegaptanib sodium ...
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) AT (Completed) DK (Completed) ES (Completed) GB (Completed) PT (Completed) BE (Completed) DE (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-005034-36 Sponsor Protocol Number: KWI-300-104 Start Date*: 2008-07-15
    Sponsor Name:Apotex Inc.
    Full Title: A non comparative, multicentre, repeat dose safety in use study of Neukine® (Filgrastim) in patients receiving chemotherapy known to induce neutropenia
    Medical condition: Febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016288 Febrile neutropenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) AT (Completed) PL (Completed) BG (Completed) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003780-50 Sponsor Protocol Number: B1871008 Start Date*: 2008-07-30
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
    Full Title: A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
    Medical condition: Chronic myelogenous leukemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (Completed) BE (Completed) ES (Completed) LV (Completed) LT (Completed) FR (Completed) IT (Completed) SI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 12:55:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA